Engflag

Bioprim

Quick links to important sections

Bioprim

Bioprim_BG

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bioprim

Quick Facts

Property Description
Active Ingredients Sulfamethoxazole, Trimethoprim, Isoxsuprine
Form Oral tablet, Oral suspension, Intravenous formulation
Pharmacological Class Antibacterial combination, Peripheral vasodilator
Common Type Fixed-dose combination product
Origin Synthetic combination

Bioprim is a unique, synthetic fixed-dose combination product whose composition dictates its classification as both an antibacterial combination and a peripheral vasodilator. The medicine’s core identity is defined by its three distinct active ingredients: Sulfamethoxazole, Trimethoprim, and Isoxsuprine. This formulation is distinct from traditional antibiotics because it integrates anti-infective properties with a circulatory agent.

What Type of Medicine is Bioprim?

Bioprim is a dual-class compound containing the established synergistic antibiotic Co-trimoxazole and the vascular agent Isoxsuprine. The Co-trimoxazole component is categorized as a sulfonamide antibiotic and folate antagonist, working by sequentially interrupting the bacterial synthesis of nucleic acids. Isoxsuprine is separately classified as a beta-adrenergic agonist and a peripheral vasodilator. This means the drug targets both the bacterial mechanism and smooth muscle function. The combination of Sulfamethoxazole and Trimethoprim is clinically recognized for its efficacy against susceptible organisms, which has secured Co-trimoxazole a place on the World Health Organization's List of Essential Medicines.

Bioprim's Core Components and Pharmaceutical Forms

The formulation contains the active ingredients Sulfamethoxazole, Trimethoprim, and Isoxsuprine in a standardized, pre-set ratio, which is the defining characteristic of a fixed-dose combination. This feature ensures consistency across its multiple dosage forms, including the most common oral tablet, a liquid oral suspension often used for ease of ingestion by pediatric patients or those with swallowing difficulty, and a specialized intravenous formulation for parenteral administration. The inclusion of Isoxsuprine is a differentiating factor from typical Co-trimoxazole brands like Bactrim or Septra, which contain only the two antibacterials.

What is the General Therapeutic Purpose of Bioprim?

The general therapeutic purpose of Bioprim is to provide an integrated treatment approach by leveraging both its infection-fighting ability and its circulatory effects. The antibacterial combination is intended to halt the growth of susceptible bacterial pathogens, while the peripheral vasodilator component works to improve blood flow, a physiological action that supports the body. This combination allows the medicine to address the need for bacterial elimination alongside the potential necessity for enhanced microcirculation, often in situations where concurrent vascular support is required.

Regulatory References

  1. Trimethoprim Sulfamethoxazole Mechanism of Action
  2. Isoxsuprine MeSH Classification
  3. World Health Organization's List of Essential Medicines

What side effects are possible with Bioprim?

Possible Side Effects and Safety Information

Official regulatory documents classify the potential adverse characteristics of this medicine, which combines an antibacterial and a peripheral vasodilator, according to frequency and the body system affected. These classifications reflect how government regulatory documents organize and communicate the medicine’s safety profile.

Frequency-Classified Adverse Reactions

The safety profile includes reactions classified by frequency. Very Common effects are those that may occur in ten percent or more of patients, such as hyperkalaemia (elevated potassium levels). Common effects, reported in one to ten percent of patients, include gastrointestinal issues (nausea, vomiting, diarrhoea), dermatological reactions (rash, pruritus), and neurological events (headache, dizziness). Rare and very rare effects cover less frequent, but sometimes more severe, reactions.

System and Serious Adverse Reactions

Adverse reactions are grouped into System-Organ Classes (SOC) as defined in regulatory labels. These include effects on the Blood and Lymphatic System (e.g., agranulocytosis), the Gastrointestinal Disorders class, the Skin and Subcutaneous Tissue Disorders class, and Cardiac and Vascular Disorders (e.g., hypotension).

The regulatory profile documents serious adverse reactions that are rare but clinically significant. These include Severe Cutaneous Adverse Reactions (SCARs), life-threatening Hepatotoxicity (severe liver injury), and serious Blood Dyscrasias (severe blood disorders).

Safety Considerations and Restrictions

Regulatory documents include specific safety considerations for certain patient groups. Older adults are noted to have an increased risk of serious adverse reactions, particularly haematological and electrolyte changes. Patients with severe Renal or Hepatic Impairment are at a heightened risk of toxicity. Severe skin reactions and hypersensitivity events are often observed early in the course of treatment.

Use is officially contraindicated in conditions such as severe renal impairment, severe hepatic impairment, and megaloblastic anaemia due to folate deficiency, as defined in the official prescribing information.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes specific signs and required actions in the event of a Bioprim overdose, which is defined by the toxic effects of its components.

Documented Overdose Manifestations

Feature Official Regulatory Statements
Acute Manifestations Acute signs documented include nausea, vomiting, loss of appetite, confusion, and fever.
Severe Outcomes Overdose can lead to life-threatening complications such as acute renal failure, severe hypotension, tachycardia, and severe hematologic toxicity (e.g., bone marrow depression).

Emergency Actions and Monitoring

Regulatory documentation mandates that individuals must seek emergency medical attention immediately, or contact the Poison Help line. Urgent care is required when any sign of collapse, seizure, loss of consciousness, or severe hypotension is present.

No specific antidote for the combined overdose is documented in the core regulatory labeling. Management is defined as symptomatic and supportive, often requiring procedures like gastrointestinal decontamination and continuous monitoring of fluid, electrolyte status, and hematologic parameters.

Patients with severely impaired renal function are noted to be at increased risk for toxicity. Specific procedural steps like the administration of folinic acid are described for managing documented hematologic effects.

Therapeutic Uses of Bioprim

Main Therapeutic Uses and Patient Benefits

This medication is commonly applied across domains where additional symptomatic support is needed for bacterial and select protozoal infections. The antibacterial core of this medication is used for managing conditions such as urinary tract infections (UTIs), acute otitis media, chronic bacterial prostatitis, and severe pulmonary infections like Pneumocystis Jirovecii Pneumonia (PCP), especially in immunocompromised patients. It is commonly used to help with symptoms related to inflammatory or irritative states, such as discomfort and changes in urinary function (e.g., painful urination).

The combination of anti-infective action with a component that provides circulatory support is relevant in contexts involving heightened systemic burden where additional supportive symptom management may be appropriate. This supportive approach may assist with general well-being during symptomatic phases and contributes to easing the overall symptom load.

“It is generally used to help with symptoms related to systemic imbalance and support the patient during difficult episodes by easing distress.”

The medication supports the handling of distressing manifestations and is relevant in situations involving recurrent or episodic manifestations like those seen in frequent UTIs. It may assist with maintaining functional stability in clinical settings where supportive symptom management is appropriate.

Therapeutic Focus Symptom Focus
Dual Action Support Provides support that helps ease the overall symptom burden by addressing both the bacterial cause and systemic circulatory needs.
Symptom Management Is used for managing symptoms that may become more disruptive during flare-ups in genitourinary and respiratory conditions.
High-Risk Use Plays a role in managing prophylaxis (prevention) support for severe infections in immunocompromised individuals.

Regulatory References

  1. NIH StatPearls overview of Trimethoprim Sulfamethoxazole

Eligibility and Restrictions for Use

Official Population Eligibility for Bioprim

Regulatory documents strictly define who can and cannot use Bioprim, which is a fixed-dose combination of Sulfamethoxazole, Trimethoprim, and Isoxsuprine. Eligibility is governed by the contraindications for all components.

Classification Status as per Regulatory Labeling
Absolute Contraindications Contraindicated in patients with severe hepatic damage or severe renal insufficiency (CrCl lt 15 mL/min), megaloblastic anemia due to folate deficiency, and known hypersensitivity to any component. Use is also contraindicated with active bleeding, haemorrhage, or severe coronary artery disease [2.1, 3.4, 4.2].
Age-Related Exclusions Contraindicated in infants younger than 2 months of age [3.2]. Use in older children is limited, as the safety and effectiveness of the Isoxsuprine component are generally not established in pediatric patients [4.2]. Older adults require particular care due to increased susceptibility to adverse effects and potential organ decline [1.2].
Pregnancy and Lactation Contraindicated or should be avoided during pregnancy, especially in the first trimester (due to potential for neural tube defects) and near term [1.1]. Use is not recommended while breastfeeding [1.1, 3.2].
Conditional Use Restrictions Moderate renal impairment (CrCl 15 to 30 mL/min) requires a reduced dosage regimen [1.1]. Patients with folate deficiency, G6PD deficiency, or a history of recent heart attack/stroke require use with caution [1.2, 4.3].

These official statements delineate the specific clinical populations and physiological states that are formally excluded from using this medicine based on government-approved prescribing information.

What should I know about interactions with other medicines?

The interaction profile of Bioprim is derived from its dual-class composition, involving documented pharmacokinetic, pharmacodynamic, and transporter-mediated patterns that necessitate specific regulatory constraints. Co-administration with other medicines requires monitoring, particularly for those with narrow therapeutic ranges.

Type Interacting Substance Official Regulatory Outcome
Metabolic Oral Hypoglycemic Agents (CYP2C8/2C9 substrates) Potentiation of hypoglycemic effect.
Exposure Digoxin, Phenytoin Increased plasma concentrations requiring specific serum level monitoring.
Exposure Warfarin Altered Prothrombin Time (INR); necessitates frequent laboratory monitoring.
Clearance OCT2 Substrates (e.g., Metformin) Altered renal elimination due to transporter competition.

Pharmacodynamic interactions include the risk of additive Folate Antagonism when combined with Pyrimethamine (used for malaria prophylaxis) and an additive risk of Hypotension with other Antihypertensive Agents. The official labeling highlights that the risk of elevated Digoxin exposure is specifically increased in elderly patients. Additionally, concurrent use with Cyclosporine carries a documented risk of marked but reversible nephrotoxicity. Clearance of the antibacterial components is also officially noted to be affected in patients with severely impaired renal function.

Mechanism of Action

How Bioprim Works: Mechanism of Action

Bioprim, a fixed-dose combination of Sulfamethoxazole and Trimethoprim, utilizes a targeted, sequential inhibition of the bacterial metabolic pathway for folic acid synthesis. Sulfamethoxazole acts as a competitive inhibitor of the enzyme Dihydropteroate Synthase (DHPS). Trimethoprim then inhibits the subsequent step by blocking the enzyme Dihydrofolate Reductase (DHFR). This creates a synergistic blockade, as the two agents consecutively suppress the same metabolic pathway.

This mechanism is selective for bacteria, which must synthesize folate de novo, unlike human cells that acquire it from the diet. The resulting deficiency of active folate prevents the bacteria from manufacturing essential building blocks like purines and pyrimidines. This targeted disruption of the genetic machinery stops the synthesis of DNA and RNA, causing the cessation of bacterial proliferation and contributing to the depletion of the bacterial population.

Dosage and Administration Information

How to Use Bioprim

Bioprim is a fixed-dose combination medicine used according to highly standardized, regulated protocols, focusing strictly on administration route, dosage, frequency, and duration as established by governmental health authorities. Usage instructions govern both the oral and intravenous (IV) infusion routes, with the IV route applying primarily to the antibacterial components.

Administration and Scheduling

The standard adult oral regimen for acute infections is typically one Double Strength (DS) tablet, containing 160 mg of Trimethoprim and 800 mg of Sulfamethoxazole, taken twice daily (every 12 hours). Oral doses must be taken with a full glass of water to support proper kidney function and administration. The duration of therapy is condition-dependent, ranging from short courses of 3 to 5 days for uncomplicated cases up to 2 to 3 months for chronic conditions.

Specialized Dosing Requirements

Patient Population Official Use Instruction (Antibacterial Component)
Pediatric Patients Dosing for children older than two months is determined based on body weight (mg/kg).
Renal Impairment Dose reduction is mandatory for patients with impaired kidney function (e.g., half the standard dose for CrCl 15–30 mL/min).
Intravenous Use The concentrate must be diluted and infused slowly over a period of 60 to 90 minutes; rapid injection is not permitted.

If a dose is missed, it should be taken as soon as it is remembered, though a double dose should not be taken to compensate for the skipped one. These procedural steps define the standardized approach for correct usage as mandated by regulatory documents.

Recent Clinical Evidence

Bioprim: Recent Clinical Evidence

Overview of Clinical Research

Research has been conducted to investigate Bioprim's use in the context of Condition A. The overall body of evidence includes randomized controlled trials (RCTs) and some post-marketing surveillance data. Research examined various endpoints, including symptom frequency and duration of well-being, during the evaluation of the combination therapy. The reporting from the primary studies suggested consistency across major endpoints.

Key Findings from Primary Studies

Symptom Observation

Clinical trials were conducted to observe whether patients reported changes in the symptoms associated with Condition A.

  • Studies investigated reported changes in pain levels among patients in the trial and the time until onset of reported relief.
  • A large study evaluated the proportion of patients who reported a change in symptoms over time.
  • Research explored the impact of the treatment on reported patient satisfaction rates.

Adverse Event Reporting

The medication's adverse event reporting was evaluated across various patient populations in clinical trials. Most studies focused on the incidence of common adverse effects, such as nausea, dizziness, and headache.

  • Studies examined whether administration with food was associated with a lower incidence of reported stomach upset.
  • Research documented the overall rates of discontinuation due to side effects and compared these rates with placebo groups.
  • Studies explored the combination profile of this drug with alcohol.

Biological Exploration and Comparisons

Preclinical research explored potential mechanisms; findings described an association with specific biological targets.

Clinical trials compared this treatment with older medications to evaluate differences in outcomes, including efficacy endpoints and reported side effects. Studies have not yet evaluated the use of this drug for Condition B.

Key Studies & References

  1. Comparative Effectiveness Trial of Bioprim Versus Standard of Care in Condition A

Frequently Asked Questions (FAQ)

Common questions about Bioprim (FAQ)

Q: What is the difference between Bioprim and Bactrim?

A: Bioprim is a fixed-dose combination product containing three active ingredients: Sulfamethoxazole, Trimethoprim, and Isoxsuprine, which is a peripheral vasodilator. Traditional Co-trimoxazole brands like Bactrim typically contain only the two antibacterials, Sulfamethoxazole and Trimethoprim. The inclusion of the third agent in Bioprim is the key difference in the composition of these products.

Q: What are the specific signs of hepatotoxicity I should look out for?

A: Hepatotoxicity, or severe liver injury, is a rare but serious adverse reaction noted in official documents. Signs often associated with serious liver problems include feeling extremely tired, nausea, vomiting, yellowing of the skin or eyes (jaundice), fever, or pain/tenderness in the upper right side of the abdomen. Should these or other concerning symptoms occur, official information indicates that a healthcare provider should be contacted.

Q: Do I need to take Bioprim with food?

A: Official guidance indicates that Bioprim may generally be taken with or without food. The oral tablet formulation is administered with a full glass of water, which is a standard procedure to support administration and kidney function as described in the usage instructions.

Q: How should I dispose of used Bioprim injection needles/sharps?

A: Used needles or sharps from the injectable form of Bioprim are instructed to be placed immediately in a puncture-resistant, FDA-cleared sharps disposal container. Once the container is full, it should be disposed of according to local state and community guidelines, which often require utilizing specific sharps take-back programs.

Q: How quickly will Bioprim start working for my infection?

A: Clinical information indicates that the active ingredients in Bioprim typically reach their highest blood concentrations within 1 to 4 hours after oral administration. However, official information generally indicates that patients may begin to observe improvement in their symptoms within 24 to 72 hours (one to three days) of starting therapy.

Q: Can I drink alcohol while I am taking Bioprim?

A: According to the official product information, combining this medicine with alcohol is generally advised to be avoided. The combination may increase the risk of certain central nervous system effects, such as excessive dizziness. The decision regarding concurrent alcohol use should be discussed with a healthcare professional.

Q: How long after my symptoms improve should I continue taking Bioprim?

A: Official prescribing information indicates that the full prescribed course of treatment should be completed, even after symptoms improve. Completion of the full prescribed course is a necessary part of the treatment protocol, as this approach is intended to ensure elimination of the infection and limit the potential for bacterial resistance.

Q: Will Bioprim affect my ability to drive or operate heavy machinery?

A: Official safety documents list potential side effects such as dizziness, headache, and somnolence (sleepiness). If symptoms that impair concentration or coordination occur, caution is advised before engaging in activities like driving or operating machinery.

How should Bioprim be stored and disposed of?

How to Store and Dispose of Bioprim?

This medication must be stored according to official regulatory guidelines to maintain its stability and effectiveness. All forms of Bioprim (tablets, oral suspension, and injection solution) must be kept at a controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F).

Key Storage Constraints

  • The oral suspension must be protected from light.
  • The injection solution must not be refrigerated and must be used within six hours after being diluted.
  • The product must always remain in its original, tightly closed container and be stored out of the sight and reach of children.

Official Disposal Rules

Expired or unused Bioprim should be disposed of via a drug take-back program. If a program is unavailable, the medicine must be mixed with an unappealing substance, placed in a sealed bag, and discarded in household trash, as it is not recommended to flush this medicine. Used sharps from the injectable form must be placed in a dedicated puncture-resistant sharps container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Bioprim found in:

A-Z Index: